D Lawes1, A Chopada, A Gillams, W Lees, I Taylor. 1. Department of Surgery, Royal Free and University College London Medical School, University College London, London UK. lawes.daniel@mayo.edu
Abstract
INTRODUCTION: Patients with liver metastasis from breast cancer have a poor prognosis, although this may be improved by hepatectomy in a selected group with disease confined to the liver. We evaluate the effectiveness of radiofrequency ablation (RFA) as a cytoreductive strategy in the management of liver metastasis from primary breast cancer. PATIENTS AND METHODS: Nineteen patients with hepatic metastasis from primary breast cancer underwent RFA of their liver lesions between April 1998 and August 2004. RESULTS: The median age of the patients was 52 years (range, 32-69 years), 8 had disease confined to the liver, with 11 having stable extrahepatic disease in addition. Seven patients with disease confined to the liver at presentation are alive, as are 6 with extrahepatic disease, median follow-up after RFA was 15 months (range, 0-77 months). Survival at 30 months was 41.6%. In addition, 7 patients followed up for a median of 14 months (range, 2-29 months) remain alive and disease-free. RFA failed to control hepatic disease in 3 patients. RFA was not associated with any mortality or major morbidity. CONCLUSIONS: Control of hepatic metastasis from breast cancer is possible using RFA and may lead to a survival benefit, particularly in those patients with disease confined to the liver.
INTRODUCTION:Patients with liver metastasis from breast cancer have a poor prognosis, although this may be improved by hepatectomy in a selected group with disease confined to the liver. We evaluate the effectiveness of radiofrequency ablation (RFA) as a cytoreductive strategy in the management of liver metastasis from primary breast cancer. PATIENTS AND METHODS: Nineteen patients with hepatic metastasis from primary breast cancer underwent RFA of their liver lesions between April 1998 and August 2004. RESULTS: The median age of the patients was 52 years (range, 32-69 years), 8 had disease confined to the liver, with 11 having stable extrahepatic disease in addition. Seven patients with disease confined to the liver at presentation are alive, as are 6 with extrahepatic disease, median follow-up after RFA was 15 months (range, 0-77 months). Survival at 30 months was 41.6%. In addition, 7 patients followed up for a median of 14 months (range, 2-29 months) remain alive and disease-free. RFA failed to control hepatic disease in 3 patients. RFA was not associated with any mortality or major morbidity. CONCLUSIONS: Control of hepatic metastasis from breast cancer is possible using RFA and may lead to a survival benefit, particularly in those patients with disease confined to the liver.
Authors: S A Curley; F Izzo; P Delrio; L M Ellis; J Granchi; P Vallone; F Fiore; S Pignata; B Daniele; F Cremona Journal: Ann Surg Date: 1999-07 Impact factor: 12.969
Authors: Dominique Elias; Franck Maisonnette; Michel Druet-Cabanac; Jean Francois Ouellet; Jean Marc Guinebretiere; Marc Spielmann; Suzette Delaloge Journal: Am J Surg Date: 2003-02 Impact factor: 2.565
Authors: Samdeep K Mouli; Ramona Gupta; Neil Sheth; Andrew C Gordon; Robert J Lewandowski Journal: Semin Intervent Radiol Date: 2018-04-05 Impact factor: 1.513
Authors: Maria A Cassera; Chet W Hammill; Michael B Ujiki; Ronald F Wolf; Lee L Swanström; Paul D Hansen Journal: HPB (Oxford) Date: 2011-04 Impact factor: 3.647